The integration of advanced systemic therapies such as radioligand therapy (RLT) with radiolabeled prostate-specific membrane antigen (PSMA) ligands into the prostate cancer treatment has improved clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). This evidence concerns the gene FOLH1 and prostate cancer.